19 hrs ago
Forest Announces New FETZIMAa (levomilnacipran ER capsules) Now...
FETZIMA was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder , also known as depression, in adults in July 2013.
Wed Dec 18, 2013
The Washington Post
Glaxo-Theravance's Second Lung Drug Anoro Wins U.S. Approval
GlaxoSmithKline Plc and Theravance Inc. won approval for the second lung drug in their partnership aimed at treating the third-leading cause of death in the U.S. The Food and Drug Administration today cleared Anoro Ellipta for chronic obstructive pulmonary disorder, an umbrella term for emphysema and chronic bronchitis.
Mon Dec 16, 2013
Stock Price Updates, Dividends Declaration, and Appointments in...
Today, Analysts' Corner announced new research reports highlighting Humana Inc. , Illumina Inc. , Forest Laboratories Inc. , Stryker Corp. and Unilife Corporation .
Wed Dec 11, 2013
Forest Laboratories Inc Files (8-K) Disclosing Entry into a Material...
FOREST LABORATORIES INC FILES Disclosing Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits Item 1.01.
Forest Laboratories, Inc. Announces Private Placement of Senior Notes ...
By a News Reporter-Staff News Editor at Pharma Business Week -- Forest Laboratories, Inc. announced a proposed offering of $1 billion aggregate principal amount of senior unsecured fixed rate notes due 2021 .
Analyst Moves: CVS, FRX, MMM
This morning, UBS increased its price target on shares of CVS Caremark to $77 after the joint venture with Cardinal Health was announced.
Mon Dec 09, 2013
Icahn Enterprises Holdings L.P. Files (8-K) Disclosing Regulation FD Disclosure, Other Events
Item 7.01 Regulation FD Disclosure Icahn Enterprises L.P. has attached hereto as Exhibit 99.1 a copy of updated presentation materials that it intends to use in connection with meetings with investors, groups of investors and media and in connection with presentations and speeches to various audiences.
Stock Upgrades: Time to Drink the Kool-Aid on Kraft
The Norwegian ambassador to New York has chosen to decorate his country's Christmas Tree with Edvard Munch's "The Scream."
Amid Rising Rates, Cash Outflows, High Yield Bond Issuance Jumps To $8.4B
U.S. high yield bond volume rebounded to $8.9 billion last week after posting just $1 billion during the Thanksgiving-shortened previous week, according to S&P Capital IQ/LCD.
Forest Laboratories Announces Appointments to its Executive Team
Forest Laboratories, Inc. today announced appointments to its executive leadership team.
Regado Biosciences Inc Files (8-K) Disclosing Change in Directors or...
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 5, 2013 , Regado Biosciences, Inc. appointed Michael A. Metzger as president and chief operating officer effective immediately.
Thu Dec 05, 2013
Mortgage News Daily
CFPB issues aggressive rulemaking agenda
Bottom Right Default State Name: State Name underscore: State Name dash: State Name lower underscore: State Name lower dash: State Name lower: State Abbreviation: State Abbreviation Lower: It is a continuously updated stream of news from around the web Visit throughout the day for the latest breaking news.
Forest Laboratories, Inc. Upsizes and Prices Offering of $1.2 Billion of Senior Notes Due 2021
Forest Laboratories, Inc. today announced it upsized and priced a private placement offering of $1.2 billion aggregate principal amount of its 5.00% senior unsecured notes due 2021 .
Wed Dec 04, 2013
The Motley Fool
AstraZeneca Eyes Forest Labs as Shares Rise
Long rumored to have eyed Forest Laboratories as a potential acquistion, AstraZeneca allegedly gained board approval for a $15 billion cash offer, secured advisors and started talks with Forest.
Tue Dec 03, 2013
's M&A Chatter for Tuesday December 3, 2013
The Rumor : Shares of Forest Labs spiked higher Tuesday on market chatter of a potential bid from AstraZeneca.
Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over.
Shareholder Activism Hands Forest A Quick Win
Forest Laboratories' stock trailed the Dow Jones pharma and biotech index for most of this year, but has broken free at last now that Brent Saunders, the chief executive brought in basically to appease Carl Icahn, has revealed his hand.
Stock Upgrades: Apple Is No Longer a Lemon
Lucky Sevens? Not so much. Nasdaq fell for the first time in seven sessions as the Dow , down 77, endured its steepest slide since the seventh of November.
Forest Laboratories Target of Unusually High Options Trading
Forest Laboratories saw some unusual options trading on Monday. Traders purchased 14,789 call options on the stock, AnalystRatingsNetwork reports.
Mon Dec 02, 2013
The Motley Fool
Why Olin, Forest Laboratories, and ProShares UltraShort Silver Soared Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.